| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Division of Breast and Endocrine Surgery, and 2 Department of Anatomy, St. Marianna University School of Medicine, Kawasaki, Japan
Requests for reprints: Tomohiko Ohta, Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki, 216-8511 Japan. Phone: 81-44-977-8111; Fax: 81-44-976-5964. E-mail: to{at}marianna-u.ac.jp.
BRCA1, a breast and ovarian tumor suppressor, is a phosphoprotein whose cellular expression level is regulated in a cell cycle–dependent manner. BRCA1 interacts with BARD1 to generate significant ubiquitin ligase activity which catalyzes nontraditional Lys-6-linked polyubiquitin chains. However, it is not clear how the activity is regulated and how this affects BRCA1's multiple cellular functions. Here we show that the ubiquitin ligase activity of BRCA1-BARD1 is down-regulated by CDK2. During the cell cycle, BARD1 expression can largely be categorized into three patterns: moderately expressed in a predominantly unphosphorylated form in early G1 phase, expressed at low levels in both phosphorylated and unphosphorylated forms during late G1 and S phases, and highly expressed in its phosphorylated form during mitosis coinciding with BRCA1 expression. CDK2-cyclin A1/E1 and CDK1-cyclin B1 phosphorylate BARD1 on its NH2 terminus in vivo and in vitro. Intriguingly, the BRCA1-BARD1–mediated in vivo ubiquitination of nucleophosmin/B23 (NPM) and autoubiquitination of BRCA1 are dramatically disrupted by coexpression of CDK2-cyclin A1/E1, but not by CDK1-cyclin B1. The inhibition of ubiquitin ligase activity is not due to the direct effect of the kinases on BARD1 because an unphosphorylatable mutant of BARD1, S148A/S251A/S288A/T299A, is still inhibited by CDK2-cyclin E1. Alternatively, BRCA1 and BARD1 are likely exported to the cytoplasm and their expressions are remarkably reduced by CDK2-cyclin E1 coexpression. Recognizing the importance of cyclin E1 overexpression in breast cancer development, these results suggest a CDK2-BRCA1-NPM pathway that coordinately functions in cell growth and tumor progression pathways.
Key Words: BARD1 • BRCA1 • CDK2 • Nucleophosmin • Ubiquitin
This article has been cited by other articles:
|
|
 |
|
  A. Viera, J. S. Rufas, I. Martinez, J. L. Barbero, S. Ortega, and J. A. Suja CDK2 is required for proper homologous pairing, recombination and sex-body formation during male mouse meiosis J. Cell Sci., June 15, 2009; 122(12): 2149 - 2159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ryser, E. Dizin, C. E. Jefford, B. Delaval, S. Gagos, A. Christodoulidou, K.-H. Krause, D. Birnbaum, and I. Irminger-Finger Distinct Roles of BARD1 Isoforms in Mitosis: Full-Length BARD1 Mediates Aurora B Degradation, Cancer-Associated BARD1{beta} Scaffolds Aurora B and BRCA2 Cancer Res., February 1, 2009; 69(3): 1125 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nishikawa, W. Wu, A. Koike, R. Kojima, H. Gomi, M. Fukuda, and T. Ohta BRCA1-Associated Protein 1 Interferes with BRCA1/BARD1 RING Heterodimer Activity Cancer Res., January 1, 2009; 69(1): 111 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okuwaki The Structure and Functions of NPM1/Nucleophsmin/B23, a Multifunctional Nucleolar Acidic Protein J. Biochem., April 1, 2008; 143(4): 441 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Falini, I. Nicoletti, N. Bolli, M. P. Martelli, A. Liso, P. Gorello, F. Mandelli, C. Mecucci, and M. F. Martelli Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias Haematologica, April 1, 2007; 92(4): 519 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Mukhopadhyay, E. A. Sausville, J. H. Doroshow, and K. K. Roy Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells: SIGNALING EVENTS MEDIATED BY HEPATOCYTE GROWTH FACTOR RECEPTOR, c-Met, AND p38 MAPK PATHWAYS J. Biol. Chem., December 8, 2006; 281(49): 37330 - 37344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chen, A. K. Seth, and A. E. Aplin Genetic and Expression Aberrations of E3 Ubiquitin Ligases in Human Breast Cancer Mol. Cancer Res., October 1, 2006; 4(10): 695 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Deans, K. K. Khanna, C. J. McNees, C. Mercurio, J. Heierhorst, and G. A. McArthur Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers Cancer Res., August 15, 2006; 66(16): 8219 - 8226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-S. Kim, H. Li, M. Cevher, A. Parmelee, D. Fonseca, F. E. Kleiman, and S. B. Lee DNA Damage-Induced BARD1 Phosphorylation Is Critical for the Inhibition of Messenger RNA Processing by BRCA1/BARD1 Complex. Cancer Res., May 1, 2006; 66(9): 4561 - 4565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Choudhury, H. Xu, A. P. Modi, W. Zhang, T. Ludwig, and R. Baer Hyperphosphorylation of the BARD1 Tumor Suppressor in Mitotic Cells J. Biol. Chem., July 1, 2005; 280(26): 24669 - 24679. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
